Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma

Management of checkpoint inhibitor-induced immune-related adverse events (irAEs) is primarily based on expert opinion. Recent studies have suggested detrimental effects of anti-tumor necrosis factor on checkpoint-inhibitor efficacy. To determine the association of toxic effect management with progression-free survival (PFS), overall survival (OS), and melanoma-specific survival (MSS) in patients with advanced melanoma treated with first-line ipilimumab-nivolumab combination therapy …
Continua a leggere

Neoadjuvant relatlimab and nivolumab in resectable melanoma

Relatlimab and nivolumab combination immunotherapy improves progression-free survival over nivolumab monotherapy in patients with unresectable advanced melanoma. We investigated this regimen in patients with resectable clinical stage III or oligometastatic stage IV melanoma (NCT02519322). Patients received two neoadjuvant doses (nivolumab 480 mg and relatlimab 160 mg intravenously every 4 weeks) …
Continua a leggere

Sex-Related Differences in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibition

We aimed to investigate sex-related differences in patients with advanced melanoma treated with ICI by linking the assessment of inflammatory response in peripheral blood, onset of immune-related adverse events IRAEs during therapy and treatment response in short- and long-term. For the purpose of this single-center retrospective study metastatic melanoma patients treated with ICI were included. Baseline patient characteristics …
Continua a leggere

Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial

Patients with stage IIB or IIC melanoma who undergo surgery alone are at a substantial risk for disease recurrence. Adjuvant pembrolizumab significantly improved recurrence-free survival versus placebo in stage IIB or IIC melanoma in the first interim analysis of the KEYNOTE-716 trial. Here, we report results from the secondary endpoint of distant metastasis-free survival (prespecified third interim analysis), and recurrence-free survival with longer follow-up …
Continua a leggere

Induction Exposure Dose of Ipilimumab and Failure of Adjuvant Nivolumab Plus Ipilimumab in Melanoma

The approval of ipilimumab (anti–cytotoxic T-cell lymphocyte [CTLA]4 Ab) in 2011 initiated the era of modern immunotherapy in cancer and has subsequently led to a dramatic improvement in outcomes for patients with melanoma. With the eventual success of other checkpoint blocking antibodies against programmed cell death protein 1 (PD-1; nivolumab and pembrolizumab) and more recently LAG3 (relatlimab), combination immune checkpoint blockade has become a standard for most patients. …
Continua a leggere